Abstract
The inflammatory bowel diseases (IBD) (Crohn’s disease [CD] and ulcerative colitis [UC]) are defined by chronic, intermittent inflammation of the intestines, resulting in abdominal pain, diarrhea, and rectal bleeding. These diseases have a peak incidence between 15–30 yr of age, and a combined prevalence of 200–300/100,000 in the United States, therefore representing a major cause of morbidity in young adults (1–3). The earliest steps in the pathogenesis of IBD are currently undefined. Development of significantly better medical therapies for IBD is dependent on developing a more specific understanding of the earliest stages of pathogenesis. Furthermore, reclassification of these disorders based on identification of molecular mechanisms of pathogenesis holds the promise of tailoring medical therapies to individual patients.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Calkins BM, Mendeloff AI. Epidemiology of inflammatory bowel disease. Epidemiol Rev 1986; 8: 60–91.
Gollop JH, Phillips SF, Melton III LJ, Zinmeister AR. Epidemiologic aspects of Crohn’s disease: a population based study in Olmsted County, Minnesota, 1943– 1982. Gut 1988; 29: 1943–1982.
Stonnington CM, Phillips SF, Melton III LF, Zinmeister AR. Chronic ulcerative colitis: incidence and prevalence in a community. Gut 1987; 28: 402–409.
Binder V. Genetic epidemiology in inflammatory bowel disease. Dig Dis 1998; 16: 351–355.
Tysk C, Linkberg E, Jarnerot G, Floderus-Myrhed B. Ulcerative colitis and Crohn’s disease in an unselected population of monozygotic and dizygotic twins: a study of heritability and the influence of smoking. Gut 1988; 29: 990–996.
Brentnall TA, Haggitt RC, Rabinovitch PS, Kimmey MB, Bronner MP, Levine DS, et al. Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1996; 110: 331–338.
Yang H, McElree C, Roth MP, Shanahan F, Targan SR, Rotter JI. Familial empirical risks for inflammatory bowel disease: differences between Jews and non-Jews. Gut 1993; 34: 517–524.
Bennett RA, Rubin PH, Present DH. Frequency of inflammatory bowel disease in offspring of couples both presenting with inflammatory bowel disease: differences between Jews and non-Jews. Gastroenterology 1991; 100: 1638–1643.
Zhong F, McCombs CC, Olson JM, Elston RC, Stevens FM, McCarthy CF, et al. An autosomal screen for genes that predispose to celiac disease in the western counties of Ireland. Nat Genet 1996; 14: 329–333
Concannon P, Gogolin-Ewens KJ, Hinds DA, Wapelhorst B, Morrison VA, Stirling B, et al. A second-generation screen of the human genome for susceptibility to insulin-dependent diabetes mellitus. Nat Genet 1998; 19: 292–6.
Hugot JP, Laurent-Puig P,Gower-Rousseau C, Olson JM, Lee JC, Beaugerie L, et al. Mapping of a susceptibility locus for Crohn’s disease on chromosome 16. Nature 1996; 379, 821–823.
Satsangi J, Parkes M, Louis E, Lathrop M, Bell J, Jewell DP. Two stage genomewide search in inflammatory bowel disesae provides evidence for susceptibility loci on chromosomes 3, 7 and 12. Nat Genetics 1996; 14: 199–202.
Cho JH, Nicolae DL, Gold LH, Fields CT, LaBuda MC, Rohal PM, et al. Identification of susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: Evidence for epistasis between 1p and IBD1. Proc Natl Acad Sci USA 1998; 95: 7502–7507.
Hampe J, Schreiber S, Shaw SH, Lau KF, Bridger S, Macpherson AJ, et al. A genomewide analysis provides evidence for novel linkages in inflammatory bowel disease in a large European cohort. Am J Hum Genet 1999; 64: 808–816.
Ma Y, Ohmen JD, Li Z, Bentley LG, McElree C, Pressman S, et al. A genomewide search identifies potential new susceptibility loci for Crohn’s disease. Inflamm Bowel Dis 1999; 5: 271–278
Duerr RH, Barmada MM, Zhang L, Pfutzer R, Weeks DE. High-density genome scan in Crohn disease shows confirmed linkage to chromosome 14q1 1–12. Am J Hum Genet 2000; 66: 1857–1862.
Rioux JD, Silverberg MS, Daly MJ, Steinhart AH, McLeod RS, Griffiths AM, et al. Search in Canadian Families with Inflammatory Bowel Disease Reveals Two Novel Susceptibility Loci. Am J Hum Genet 2000; 66: 1863–1870.
Lee JCW, Lennard-Jones JE. Inflammatory bowel disease in 67 families each with three or more affected first-degree relatives. Gastroenterology 1996; 111: 587–596.
Becker KG, Simon RM, Bailey-Wilson JE, Freidlin B, Biddison WE, McFarland HF, et al. Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases. Proc Natl Acad Sci 1998; 95: 9979–9984.
Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et al. A frame-shift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature 2001; 411: 603–606.
Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 2001; 411: 599–603.
Hampe J, Cuthbert A, Croucher PJ, Mirza MM, Mascheretti S, Fisher S, et al. Association between insertion mutation in NOD2 gene and Crohn’s disease in German and British populations. Lancet 2001; 357 (9272): 1925–1928.
Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G. Impaired on/ off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 1999; 10: 387–398.
McGuire W, Hill AV, Allsopp CE, Greenwood BM, Kwiatkowski D. Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. Nature 1994; 371: 508–510.
Negoro K, Kinouchi Y, Hiwatashi N, Takahashi S, Takagi S, Satoh J, et al. Crohn’s disease is associated with novel polymorphisms in the 5’-flanking region of the tumor necrosis factor gene. Gastroenterology 1999; 117: 1062–1068.
Tountas NA, Casini-Raggi V, Yang H, Di Giovine FS, Vecchi M, Kam L, et al. Functional and ethnic association of allele 2 of the interleukin-1 receptor antagonist gene in ulcerative colitis. Gastroenterology 1999; 117: 806–813.
Olavesen MG, Hampe J, Mirza MM, Saiz R, Lewis CM, Bridger S, et al. Analysis of single-nucleotide polymorphisms in the interleukin-4 receptor gene for association with inflammatory bowel disease. Immunogenetics 2000; 51: 1–7.
Orchard TR, Thiyagaraja S, Welsh KI, Wordsworth BP, Hill Gaston JS, Jewell DP. Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology 2000; 118: 274–278.
Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Theoret Y, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705–713.
Liptay S, Bachem M, Hacker G, Adler G, Debatin KM, Schmid RM. Inhibition of nuclear factor kappa B and induction of apoptosis in T-lymphocytes by sulfasalazine. Br J Pharmacol 1999; 128: 1361–1369.
Farrell RJ, Murphy A, Long A, Donnelly S, Cherikuri A, O’Toole D, et al. High multi drug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology 2000; 118: 279–288.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer Science+Business Media New York
About this chapter
Cite this chapter
Cho, J. (2003). Genetics of Inflammatory Bowel Disease. In: Cohen, R.D. (eds) Inflammatory Bowel Disease. Clinical Gastroenterology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-311-8_4
Download citation
DOI: https://doi.org/10.1007/978-1-59259-311-8_4
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-4757-5465-0
Online ISBN: 978-1-59259-311-8
eBook Packages: Springer Book Archive